Dianthus Therapeutics financials
$87.16−0.76%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M |
| Gross profit | $2.0M | $6.2M | $2.8M |
| Gross margin | 100.0% | 100.0% | 100.0% |
| Operating income | -$177.9M | -$101.9M | -$48.2M |
| Net income | -$162.3M | -$85.0M | -$43.6M |
| Net margin | −7973.3% | −1362.8% | −1541.2% |
| Diluted EPS | $-4.20 | $-2.55 | $-8.45 |
| EBITDA | -$177.8M | -$101.8M | -$48.1M |
| Operating cash flow | -$129.1M | -$78.2M | -$36.9M |
| Free cash flow | -$129.3M | -$78.3M | -$37.0M |
| Diluted shares | 38.6M | 33.3M | 5.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $51.1M | $22.8M | $132.3M |
| Short-term investments | $353.2M | $252.4M | $41.4M |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $530.9M | $374.0M | $179.4M |
| Total liabilities | $37.5M | $21.5M | $10.5M |
| Shareholders' equity | $493.4M | $352.5M | $168.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology